

Short and long-term cost-effectiveness of switching therapy from insulin glargine to insulin detemir in people with type 2 diabetes

- Rachid Malek**
Internal Medicine, CHU Sétif, Algeria
- Guillermo González Gálvez**
Instituto Jalisciense de Investigación en Diabetes y Obesidad, Guadalajara, Mexico
- Eva Hammerby**
Novo Nordisk A/S, Copenhagen, Denmark
- Annie Nikolajsen**
Novo Nordisk A/S, Copenhagen, Denmark
- Frederikke Bruun Andersen**
Last Mile P/S, Copenhagen, Denmark
- Ole Henriksen**
Last Mile P/S, Copenhagen, Denmark

Objective

- To assess the cost-effectiveness (CE) of switching therapy from insulin glargine ± oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with type 2 diabetes (T2DM) in countries in different economic circumstances based on the A₁chieve® study - an observational study evaluating adverse events and effectiveness of Novo Nordisk insulin analogs in routine clinical practice.

Methods

- The A₁chieve® study is a non-interventional 24 week study including more than 66,000 people with T2DM from 28 countries starting either biphasic insulin aspart 30, insulin detemir and/or insulin aspart.
- The CE analyses included data for people switching to insulin detemir in Saudi Arabia (n=102) and South Korea (n=82), as well as in 3 North-West African countries* (n=94) using Algeria health costs. Data were collected on clinical effectiveness, adverse events and health-related quality of life using the EQ-5D questionnaire.
- Short-term incremental costs-effectiveness ratios (ICERs) were computed based on incremental cost of treatment and the EQ-5D incremental effect in the first year after switching to insulin detemir.
- Long-term ICERs were simulated using the IMS CORE Diabetes Model¹ with 30-year time horizon including country-specific costs for complications and therapies and background mortality rates.
- ICERs are expressed as cost per QALY in local currencies, USD and in fractions of local GDP per capita. CE was pre-defined using the WHO Choice programme threshold based on GDP per capita².
- The robustness of the estimated ICERs were tested in a series of sensitivity analyses including; expansion of the simulation time horizon from 30 to 50-years, assuming no deterioration of glucose control with time, assuming median and first quartile distribution of treatment effects on HbA_{1c}, including the costs of self-monitoring blood glucose (SMBG) strips and including the costs of 1 and 2 additional general practitioner (GP) visits in the first year after switching to insulin detemir.

Results

- Across all country settings, 59% of the 3000 bootstrap replications of ICERs were dominant and 41% were highly cost-effective based on a 30-year time horizon (see figure 2).
- Predicted life-expectancy increased in both Saudi Arabia (0.96) and South Korea (0.74) and Algeria (0.26) (see figure 3).
- The relative risk of developing selected complications was reduced substantially in both countries (see figure 4).

Conclusions

- Switching therapy from insulin glargine to insulin detemir in T2DM as performed in the A₁chieve® study was found to be highly cost-effective across all country settings based on a 1 and 30-year time horizon.
- Sensitivity analyses showed the long-term cost-effectiveness to be robust.
- Predicted life-expectancy increased and the relative risk of complications was reduced across all country settings based on a 30-year time horizon.

Figure 1 Treatment effect on HbA_{1c} at baseline and at week 24.




Figure 2 Improvements in patient reported outcomes using the EQ-5D questionnaire when switching to insulin detemir.




Figure 3 ICER scatterplot displaying 3000 bootstrap replications (1000 per country) of incremental costs as GDP per capita and incremental quality-adjusted life expectancy (Incremental QALE)*.




Figure 4 Current life expectancy in the general population and simulated life expectancy at baseline and in people switching to insulin detemir.




Figure 5 Relative risk reduction in selected complications over 30 years simulated in the IMS CORE Diabetes Model¹.




Table 1 1-year and 30-year ICERs (base case) per QALY gained.

Country	1-year ICER			30-year ICER (base case)		
	Local currency	USD	Fraction of GDP	Local currency	USD	Fraction of GDP
Saudi Arabia	SAR -5,849	-1,559	-0.08	SAR -14,839	-3,957	-0.19
South Korea	KRW 296,842	273	0.01	KRW -1,133,202	-1,043	-0.05
Algeria	DZD 267,771	3,363	0.80	DZD 226,818	2,849	0.68

Table 2 Sensitivity analyses presented as fraction of GDP per capita per QALY gained.

Country	50-year time horizon	No HbA _{1c} deterioration	Median treatment effect (HbA _{1c})	Quarter 1 treatment effect (HbA _{1c})	Including costs of SMBG strips	1 additional GP visit in the first year after switch	2 additional GP visits in the first year after switch
Saudi Arabia	-0.18	-0.16	-0.18	-0.15	-0.19	-0.19	-0.19
South Korea	-0.04	-0.06	-0.04	-0.00	-0.04	-0.05	-0.04
Algeria	0.67	0.68	0.68	0.99	0.68	0.68	0.68

*Algeria, Tunisia and Morocco

¹The IMS Core Diabetes Model (CDM) is an interactive computer simulation model of diabetes (type 1 and type 2), comprising 15 inter-dependent sub-models accounting for the complications related to diabetes. Each Markov sub-model uses time-, state-, and diabetes type-dependent probabilities derived from published sources to obtain projected outcomes relevant to specific patient groups and country settings of interest. Patient cohorts are defined in terms of age, gender, baseline risk factors and pre-existing complications. Disease management components and costs are loaded into the CDM based on local data as well as background mortality rates for causes of death not determined by the CDM¹.

²The World Health Organization (WHO) Choice programme² recommends a threshold based on GDP per capita. A health technology is labelled:

- "Not cost-effective" – if costs ≥ 3 times GDP per capita
- "Cost-effective" – if costs ≥ 1 and ≤ 3 times GDP per capita
- "Highly cost-effective" – if costs ≤ GDP per capita

The health technology is referred to as "Dominant" if the costs per life year gained are below 0

³ Average switch-specific p-value.

1. Palmer AJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. *Curr Med Res Opin.* 2004;20(8):5-26
2. WHO Choice Programme. Available online at: http://www.who.int/choice/costs/CER_thresholds/en/index.html